What was the overall market valuation of the GCC compounding chemotherapy market in 2024?

The overall market valuation was $13.25 Million in 2024. Read More

What is the projected market valuation for the GCC compounding chemotherapy market by 2035?

The projected valuation for 2035 is $25.18 Million. Read More

What is the expected CAGR for the GCC compounding chemotherapy market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 6.01%. Read More

Which companies are considered key players in the GCC compounding chemotherapy market?

Key players include Fresenius Kabi, Baxter International, Civica Rx, PharMEDium Services, Accredo Health Group, B. Braun Melsungen AG, Scripps Health, and Athenex. Read More

What were the segment valuations for chemotherapeutic and non-chemotherapeutic doses in 2024?

In 2024, the segment valuation for chemotherapeutics was $8.0 Million, while non-chemotherapeutics was $5.25 Million. Read More

How do the valuations for gravimetric and volumetric automated compounding devices compare in 2024?

In 2024, gravimetric automated compounding devices were valued at $5.3 Million, whereas volumetric devices were valued at $7.95 Million. Read More

What was the valuation for sterile and non-sterile compounding in 2024?

The valuation for sterile compounding was $8.25 Million, while non-sterile compounding was $5.0 Million in 2024. Read More

What are the projected valuations for compounding technology with and without robotic arms by 2035?

By 2035, compounding technology with robotic arms is projected to reach $10.5 Million, while without robotic arms, it is expected to reach $14.68 Million. Read More

What does the market data suggest about the growth of the GCC compounding chemotherapy market?

The market data suggests a steady growth trajectory, with a projected increase from $13.25 Million in 2024 to $25.18 Million by 2035. Read More

How does the market performance of sterile versus non-sterile compounding appear in the current landscape?

The market performance indicates that sterile compounding, valued at $8.25 Million, outperforms non-sterile compounding, which was valued at $5.0 Million in 2024. Read More

GCC Compounding Chemotherapy Market

ID: MRFR/Pharma/51475-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

GCC Compounding Chemotherapy Market Research Report By Dose (Chemotherapeutic, Non-Chemotherapeutics), By Delivery Method (Gravimetric Automated Compounding Device, Volumetric Automated Compounding Device), By Sterility (Sterile, Non-Sterile), and By Technology (With Robotic Arms, Without Robotic Arms) - Growth & Industry Forecast 2025 To 2035

GCC Compounding Chemotherapy Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Dose (USD Million)
  1. 4.1.1 Chemotherapeutic
  2. 4.1.2 Non-Chemotherapeutics
2. 4.2 Construction, BY Delivery Method (USD Million)
  1. 4.2.1 Gravimetric Automated Compounding Device
  2. 4.2.2 Volumetric Automated Compounding Device
3. 4.3 Construction, BY Sterility (USD Million)
  1. 4.3.1 Sterile
  2. 4.3.2 Non-Sterile
4. 4.4 Construction, BY Technology (USD Million)
  1. 4.4.1 With Robotic Arms
  2. 4.4.2 Without Robotic Arms
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Fresenius Kabi (DE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Baxter International (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Civica Rx (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 PharMEDium Services (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Accredo Health Group (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 B. Braun Melsungen AG (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Scripps Health (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Athenex (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GCC MARKET ANALYSIS BY DOSE
3. 6.3 GCC MARKET ANALYSIS BY DELIVERY METHOD
4. 6.4 GCC MARKET ANALYSIS BY STERILITY
5. 6.5 GCC MARKET ANALYSIS BY TECHNOLOGY
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY DOSE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY DOSE, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY DELIVERY METHOD, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY DELIVERY METHOD, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY STERILITY, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY STERILITY, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY TECHNOLOGY, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 GCC MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DOSE, 2025-2035 (USD Million)
  2. 7.2.2 BY DELIVERY METHOD, 2025-2035 (USD Million)
  3. 7.2.3 BY STERILITY, 2025-2035 (USD Million)
  4. 7.2.4 BY TECHNOLOGY, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

GCC Construction Market Segmentation

Construction By Dose (USD Million, 2025-2035)

Chemotherapeutic
Non-Chemotherapeutics

Construction By Delivery Method (USD Million, 2025-2035)

Gravimetric Automated Compounding Device
Volumetric Automated Compounding Device

Construction By Sterility (USD Million, 2025-2035)

Sterile
Non-Sterile

Construction By Technology (USD Million, 2025-2035)

With Robotic Arms
Without Robotic Arms

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”